Drug Trial Radar · NCT04333472
Piclidenoson for Treatment of COVID-19
Last checked: Nov 20, 2026Latest source record: Apr 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Jan 6, 2021
Primary completion
Mar 6, 2022
Study completion Apr 21, 2022
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Rabin Medical Center
- First posted
- Apr 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or placebo orally with SSC (control arm) for up to 28 days.
Conditions
- COVID-19
- Coronavirus Infection
Interventions
PiclidenosonDrug
Piclidenoson 2 mg orally every 12 hours for up to 28 days
PlaceboDrug
Placebo orally every 12 hours for up to 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects alive and free of respiratory failureTime frame: 29 days
- Proportion of subjects discharged home aliveTime frame: 29 days
- Treatment-emergent adverse events (AEs)Time frame: 29 days
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
II Multiprofile Hospital for Active Treatment - Sofia EAD
Sofia, Bulgaria
IV Multiprofile Hospital for Active Treatment - Sofia EAD
Sofia, Bulgaria
Hadassah Medical Center
Jerusalem, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Clinical Hospital for Infectious Diseases "St. Parascheva" Iasi
Iași, Romania
"Sfantul Ioan cel Nou" County Emergency Hospital Suceava
Suceava, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.